Keryx Biopharmaceuticals Fends Off Investor Suit

, The Litigation Daily

   | 0 Comments

Keryx Biopharmaceuticals Inc. and its lawyers at Alston & Bird have defeated claims that the company misled investors about the results of a clinical trial for its cancer drug Perifosine.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202643220356

Thank you!

This article's comments will be reviewed.